EP0855915B1 - Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales - Google Patents

Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales Download PDF

Info

Publication number
EP0855915B1
EP0855915B1 EP97929442A EP97929442A EP0855915B1 EP 0855915 B1 EP0855915 B1 EP 0855915B1 EP 97929442 A EP97929442 A EP 97929442A EP 97929442 A EP97929442 A EP 97929442A EP 0855915 B1 EP0855915 B1 EP 0855915B1
Authority
EP
European Patent Office
Prior art keywords
topical composition
interferon
amino acid
amino acids
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97929442A
Other languages
German (de)
English (en)
Other versions
EP0855915A2 (fr
Inventor
Sandor Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0855915A2 publication Critical patent/EP0855915A2/fr
Application granted granted Critical
Publication of EP0855915B1 publication Critical patent/EP0855915B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • Subject of the patent is a topical composition containing a combination of one or more amino acids and an antiviral agent in a synergistic amount.
  • the preparation according to the patent description is advantageously applicable for augmentation of the antiviral and anti-inflammatory effects of interferons and thimidine-analogous antiherpetic drugs, for amelioration of psoriatic symptoms and further, it is an effective drug against Herpes virus infections.
  • Interferons are natural proteins with complex biological actions. Most important of their effects are antiviral, cell proliferation inhibitory and immune response enhancing properties. These effects are utilised in the human therapy. Interferons have therapeutic use in tumour bearing patients.
  • Interferons are also effective in viral infections as it can be seen in the following publications: Lancet, i, p. 128, 1976; Transplantation Proc., 21, pp 2429-2430, 1989; Interferons in the Treatment of Chronic Virus Infections of the Liver, Pennine Press, Macclesfield, 1990.
  • interferons it is usual to apply interferons in combination for therapeutic purposes in order to decrease the severity of side effects.
  • Several different approximations are applicable for combination therapies: decrease of the necessary doses by complementation with drugs of similar mechanism of action (J. Natl. Cancer Inst., 83, pp 1408-1410, 1991); combination with drugs of antagonistic mechanism of action in order to selectively reduce harmful side effects (J. Biol. Resp. Modifiers, 5, pp 447-480, 19986); selective augmentation of the required therapeutic effect by addition of potentiating components or by application of appropriate physical conditions, e.g. hyperthermia (Proc. Soc. Exp. Biol. Med., 169, pp 413, 1982).
  • thimidine-analogous drugs deoxyuridine derivatives substituted at the 5 position
  • antiherpetic action is seriously limited by that fact that a a fast viral resistance develops in response to therapeutic concentrations of these drugs.
  • Viral strains resistant to one given drug show crossresistance to other ones with similar chemical structure. Dose reduction of these drugs -if it could be achieved- would reduce the selection pressure on the viruses, thus, the frequency of the development of resistant mutants consequently enhancing the therapeutic value of the known antiherpetic agents.
  • the purpose of this invention is to enhance selectively the antiviral effects of interferons and antiherpetic thimidine-analogues in order to be able to decrease the effective therapeutic doses.
  • Our invention is based on the recognition that some amino acids are able to potentiate the antiherpetic effect of the thimidine analogue drugs by a factor of several grades (10 2 - 10 4 times) and likewise the antiviral and anti--inflammatory action of interferons without influencing other biological activities of interferons. Furthermore, the preparations are effective against Herpes viruses and alleviate or eliminate psoriatic symptoms of the skin.
  • the core of the invention is a preparation for external use, containing amino acids, advantageously augmenting antiviral and anti-inflammatory drug actions and being remedial in psoriasis.
  • the preparation is characterised by its topical composition which is containing a combination of an anti-viral agent and one or more amino-acids in a synergistic amount characterized by that it is containing an interferon and one or more of the following amino acids: D-aspartic acid, D-cysteine, D-cystine, Glycine, D-oxyproline, D-serine, D-tyrosine; or antiherpetic thymidine-analogous drugs - preferably uridine derivatives - and one or more of the following amino acids: D- or L-aspartic acid, D- or L-cysteine, D-or L-cystine, Glycine, D- or L-oxyproline, D- or L-serine, D- or L-tyrosine, and further pharmaceutical additives, preferably solvents, conservatives or known ointment bases.
  • topical composition as described above is characterized by that it is containing D-aspartic acid as amino acid.
  • topical composition as described above is characterized by that it is containing D-aspartic acid and L-oxyproline as amino acids.
  • topical composition as described above is characterized by that it is containing D-serine as amino acid.
  • a sterile solution of native human interferon alpha (HuIFN- ⁇ ) - -preferably from the preparation under trade name EGIFERON- was made in water at a concentration of 50000 international units/ml (IU/ml) under aseptic conditions.
  • the solution also contained an amino acid mixture of D-Asp and L-Ser at a concentration of 5 mg/ml for each. 20 w/v% sucrose was added as a conserving agent.
  • a sterile solution of native or recombinant human interferon gamma was made in water at a concentration of 2500 IU/ml and 15 mg/ml of D-Asp and L-Opr. 20 w/v% sucrose was added as a conserving agent.
  • a sterile solution of IDU was made in water at a concentration of 25 ⁇ g/ml. 25 mg/ml of D-Asp was dissolved in the above solution. 20 w/v% sucrose was added as a conserving agent.
  • a sterile solution of EDU was made in water at a concentration of 25 ⁇ g/ml. 1 mg/ml of L-Ser and 500 IU/ml of native or recombinant HuIFN- ⁇ was added to the above solution. 20 w/v% sucrose was used as a conserving agent.
  • Antiviral activity of a HuIFN- ⁇ was measured on WISH (human amnion epithelia) cells against Vesicular stomatitis virus (VSV) in the presence of different amino acids under different experimental conditions.
  • the antiviral test consists of 3 phases. In the 1. phase WISH cells are incubated in 96-well flat-bottom microplates until reaching monolayer stage. 100 ⁇ l aliquots of twofold seral dilutions of the HuIFN- ⁇ samples are then added to the test cells and are incubated for 20-24 hours at 37 °C in 5% CO 2 atmosphere (phase II.).
  • the IFN-treated cells are infected with a predetermined dose of VSV which can kill 100% of the unprotected WISH cells in 24 hours (phase III.).
  • the reference point of a measurement is that dilution of the IFN sample which provides protection for 50% of the infected cells at the end of the 24 hours infection period.
  • the effects of different amino acids and different conditions were compared by determining the virtual titres of HuIFN- ⁇ samples having identical nominal titres. The measurements were done:
  • Antiviral activities of different concentrations of IDU were measured on a permanent human tumour cell line (Hep2) against human Herpes simplex type 1.
  • Cells were incubated in Petri dishes until monolayer stage, then were infected with a predetermined dose of the challenge virus which can kill 100% of the unprotected cells in 72 hours. The virus was allowed for 1 hour to be adsorbed on the surface of the cells. Next, a fresh nutritive medium was given to the cells containing the drug in a concentration to be tested and the experimental system was incubated for 72 hours at 37 °C in 5% CO 2 atmosphere. The amount of virus produced in the test system was determined as follows: infected cells were disrupted, centrifuged and the supernatants were collected.
  • Herpes virus infections (HSV 1, Herpes zoster) and inflammatory skin rushes of different aetiology were treated with an ointment described in the example 5. Patients were chosen on voluntary basis and uncontrolled treatments were carried out. The results obtained are summarised in Table IV. Disease Number of cases Treatment (daily applications/ number of days) Results Notice labial herpes (HSV 1) 56 cases/27 persons 2-3/1-3 57/57 healings in 3 days At 1 person vesicles extended to the neck and breast. Healing in 3 days. Ointment applied at the onset prevent the appearance of symptoms. genital herpes (HSV 2) 1 2/7 Healing in a week Widespread ulcerous infection on the leg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

  1. Une composition topique contenante une combinaison d'un agent antiviral et d'un ou plusieurs acides aminés en quantités synergiques caractérisé par qu'elle contient un interferon et un ou plusieurs des acides aminés suivants: D-acide d'asperge, D-cystéine, D-cystine, glycine, D-oxyproline, D-sérine, D-tyrosine; ou drogues antiherpétiques analogiques au thymidine avantageusement dérivés d'uridine et un ou plusieurs des acides aminés suivants: D- ou L-acide d'asperge, D- ou L-cystéine, D- ou L-cystine, glycine, D- ou L-oxyproline, D-ou L-sérine, D- ou L-tyrosine et additifs pharmaceutiques supplémentaires avantageusement solvants, agents conservateurs ou bases des onguents connus.
  2. La composition topique selon la revendication 1 caractérisée par qu'elle contient D-acide d'asperge comme acide aminé.
  3. La composition topique selon la revendication 1 caractérisée par qu'elle contient D-acide d'asperge et L-oxyproline comme acides aminés.
  4. La composition topique selon la revendication 1 caractérisée par qu'elle contient D-sérine comme acide aminé.
EP97929442A 1996-07-25 1997-07-03 Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales Expired - Lifetime EP0855915B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9602024A HUP9602024A3 (en) 1996-07-25 1996-07-25 Pharmaceutical composition containing aminoacid for external use
HU9602024 1996-07-25
PCT/HU1997/000035 WO1998004280A2 (fr) 1996-07-25 1997-07-03 Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales

Publications (2)

Publication Number Publication Date
EP0855915A2 EP0855915A2 (fr) 1998-08-05
EP0855915B1 true EP0855915B1 (fr) 2005-06-15

Family

ID=89994154

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97929442A Expired - Lifetime EP0855915B1 (fr) 1996-07-25 1997-07-03 Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales

Country Status (9)

Country Link
US (1) US6048843A (fr)
EP (1) EP0855915B1 (fr)
AT (1) ATE297752T1 (fr)
AU (1) AU3354997A (fr)
CA (1) CA2232710A1 (fr)
DE (1) DE69733539D1 (fr)
HR (1) HRP970419A2 (fr)
HU (1) HUP9602024A3 (fr)
WO (1) WO1998004280A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
CA2393688A1 (fr) 1999-12-09 2001-06-14 Chiron Corporation Procede d'administration de cytokine aux systeme nerveux central et systeme lymphatique
US6415797B1 (en) * 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
KR20020027198A (ko) * 2000-10-02 2002-04-13 차알스 제이. 메츠 염증과 홍반의 완화방법
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
JP4382354B2 (ja) * 2001-03-13 2009-12-09 ヴァルブルク・グリコムド・ゲーエムベーハー １−ブタン酸誘導体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710376A (en) * 1985-02-01 1987-12-01 Interferon Sciences, Inc. Topical therapeutic composition containing oxidation inhibitor system
HU196038B (en) * 1987-08-07 1988-09-28 Mta Koezponti Kemiai Kutato In Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
EP0326151B1 (fr) * 1988-01-29 1993-06-16 Sumitomo Pharmaceuticals Company, Limited Formulations perfectionnées à libération contrôlée
CA1339256C (fr) * 1989-01-26 1997-08-12 Wulf Droge Traitement de maladies associees aux infections par le vih

Also Published As

Publication number Publication date
DE69733539D1 (de) 2005-07-21
ATE297752T1 (de) 2005-07-15
WO1998004280A2 (fr) 1998-02-05
US6048843A (en) 2000-04-11
HUP9602024A3 (en) 1999-05-28
HUP9602024A2 (hu) 1998-03-30
EP0855915A2 (fr) 1998-08-05
HRP970419A2 (en) 1998-08-31
WO1998004280A3 (fr) 1998-03-26
HU9602024D0 (en) 1996-09-30
AU3354997A (en) 1998-02-20
CA2232710A1 (fr) 1998-02-05

Similar Documents

Publication Publication Date Title
US4424232A (en) Treatment of herpes simplex
PEACOCK JR Pharmacologic control of surface scarring in human beings
US20150374759A1 (en) Method for Treatment of Sores and Lesions of the Skin
EP1611885A8 (fr) Utilisation d'un agent inducteur pour le traitement des maladies virales et cellulaires et du sang
Scott et al. Effect of injections of small doses of human fibroblast interferon into genital warts. A pilot study.
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
US6558656B2 (en) Oral and topical compositions and methods related thereto in the treatment of acne
EP0855915B1 (fr) Composition a usage externe contenant un acide amine en combinaison avec soit des derives de thymidine soit un interferon pour traiter les maladies inflammatoires ou virales
JP2023123440A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
EP0988040A1 (fr) Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees
CA2455776C (fr) Compositions a base d'acides amines appropriees en therapie pour guerir et/ou panser des plaies et des lesions, notamment utilisees dans le domaine de l'ophtalmologie
JP3631245B2 (ja) ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用
CZ293353B6 (cs) Farmaceutický prostředek pro prevenci nebo léčení poruchy růstu vlasů
CA1223211A (fr) Compose antiviral et methode d'administration
KR100302994B1 (ko) 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용
CA1200763A (fr) Medicment pour le traitement de certaines neuroviroses
US4753942A (en) Method for the treatment of inflammatory conditions
US6270756B1 (en) Weight loss induced by alpha interferon and gamma interferon
Castelli et al. Griseofulvin-methisoprinol combination in the treatment of herpes zoster
JPH01294635A (ja) 局所投与用製薬組成物
JP2688733B2 (ja) 消化管粘膜障害の予防及び治療剤
CN116509831A (zh) 含有藏红花酸或其可药用盐的外用制剂的用途
CA3168280A1 (fr) Composition de cicatrisation de plaies chroniques et son application
Richtsmeier The interferons
UA82062C2 (uk) Фармацевтична композиція місцевого застосування для лікування захворювань, викликаних внутрішньоклітинними інфекційними агентами

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19980925

17Q First examination report despatched

Effective date: 19991227

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 31/22 B

Ipc: 7A 61P 31/12 B

Ipc: 7A 61K 31/00 B

Ipc: 7A 61K 31/195 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 38/21 A

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050615

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050704

REF Corresponds to:

Ref document number: 69733539

Country of ref document: DE

Date of ref document: 20050721

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050915

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050915

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050915

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051123

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060201

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050915

26N No opposition filed

Effective date: 20060316

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050615